相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Absent in Melanoma 2 (AIM2) Regulates the Stability of Regulatory T Cells
Beatriz Lozano-Ruiz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
Jedd D. Wolchok et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences
Yasset Perez-Riverol et al.
NUCLEIC ACIDS RESEARCH (2022)
Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance
Lir Beck et al.
CLINICAL CANCER RESEARCH (2021)
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
Paul B. Chapman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
PDIA6 promotes pancreatic cancer progression and immune escape through CSN5-mediated deubiquitination of beta-catenin and PD-L1
Yihui Ma et al.
NEOPLASIA (2021)
Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma
Shelly Kalaora et al.
NATURE COMMUNICATIONS (2020)
In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma
Haris Babacic et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
Jeffrey C. Thompson et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
Katarzyna Tomela et al.
LIFE-BASEL (2020)
Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response
Saurabh K. Garg et al.
CANCERS (2020)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Tuba N. Gide et al.
CANCER CELL (2019)
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
Paolo A. Ascierto et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence
Michal Harel et al.
CELL (2019)
Endoplasmic Reticulum Protein Disulfide Isomerase Shapes T Cell Efficacy for Adoptive Cellular Therapy of Tumors
Katie E. Hurst et al.
CELLS (2019)
Calnexin Impairs the Antitumor Immunity of CD4+ and CD8+ T Cells
Yichen Chen et al.
CANCER IMMUNOLOGY RESEARCH (2019)
A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma
Jeffrey S. Weber et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Carl Morrison et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Functional proteomics outlines the complexity of breast cancer molecular subtypes
Angelo Gamez-Pozo et al.
SCIENTIFIC REPORTS (2017)
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Antoni Ribas et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
The Perseus computational platform for comprehensive analysis of (prote)omics data
Stefka Tyanova et al.
NATURE METHODS (2016)
Combined Label-Free Quantitative Proteomics and microRNA Expression Analysis of Breast Cancer Unravel Molecular Differences with Clinical Implications
Angelo Gamez-Pozo et al.
CANCER RESEARCH (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
High-Dimensional Graphical Model Search with thegRapHDRPackage
Gabriel C. G. Abreu et al.
Journal of Statistical Software (2015)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Shotgun proteomics of archival triple-negative breast cancer samples
Angelo Gamez-Pozo et al.
PROTEOMICS CLINICAL APPLICATIONS (2013)
MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells
Cristina Garrido et al.
CARCINOGENESIS (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Tumor Cell Programmed Death Ligand 1-Mediated T Cell Suppression Is Overcome by Coexpression of CD80
Samuel T. Haile et al.
JOURNAL OF IMMUNOLOGY (2011)
Andromeda: A Peptide Search Engine Integrated into the MaxQuant Environment
Juergen Cox et al.
JOURNAL OF PROTEOME RESEARCH (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Up-Regulation of A1M/α1-Microglobulin in Skin by Heme and Reactive Oxygen Species Gives Protection from Oxidative Damage
Magnus G. Olsson et al.
PLOS ONE (2011)
Ensembl BioMarts: a hub for data retrieval across taxonomic space
Rhoda J. Kinsella et al.
DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Da Wei Huang et al.
NATURE PROTOCOLS (2009)
MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification
Juergen Cox et al.
NATURE BIOTECHNOLOGY (2008)
Roadmap for developing and validating therapeutically relevant genomic classifiers
R Simon
JOURNAL OF CLINICAL ONCOLOGY (2005)
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials
TK Eigentler et al.
LANCET ONCOLOGY (2003)
Cytoscape: A software environment for integrated models of biomolecular interaction networks
P Shannon et al.
GENOME RESEARCH (2003)
分享论文
